Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells $249,704.00 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) Director Barbara Weber sold 5,200 shares of the company’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $48.02, for a total transaction of $249,704.00. Following the completion of the transaction, the director now directly owns 13,065 shares in the company, valued at approximately $627,381.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Revolution Medicines Trading Up 2.0 %

NASDAQ RVMD opened at $50.48 on Friday. The firm has a market cap of $8.43 billion, a PE ratio of -13.87 and a beta of 1.43. Revolution Medicines, Inc. has a 1-year low of $15.44 and a 1-year high of $51.00. The stock has a 50-day moving average of $44.10 and a 200-day moving average of $40.73.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.81 million. During the same period in the prior year, the firm earned ($0.92) EPS. The business’s revenue was down 73.8% on a year-over-year basis. As a group, equities research analysts forecast that Revolution Medicines, Inc. will post -3.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Wedbush restated an “outperform” rating and issued a $59.00 target price on shares of Revolution Medicines in a research note on Thursday, August 8th. JPMorgan Chase & Co. lowered their target price on shares of Revolution Medicines from $55.00 to $54.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC reissued a “buy” rating and issued a $61.00 price target on shares of Revolution Medicines in a research note on Monday, October 7th. Bank of America raised their price objective on shares of Revolution Medicines from $48.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Finally, Jefferies Financial Group initiated coverage on shares of Revolution Medicines in a research report on Monday, July 8th. They issued a “buy” rating and a $63.00 target price for the company. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $54.00.

Institutional Investors Weigh In On Revolution Medicines

Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Revolution Medicines by 55.8% during the third quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $28,000 after purchasing an additional 222 shares during the period. Headlands Technologies LLC increased its stake in shares of Revolution Medicines by 140.9% during the first quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock valued at $49,000 after buying an additional 885 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of Revolution Medicines during the first quarter valued at approximately $104,000. EntryPoint Capital LLC bought a new position in shares of Revolution Medicines during the first quarter valued at approximately $107,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Revolution Medicines by 10.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock valued at $131,000 after acquiring an additional 320 shares in the last quarter. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.